LMGF(SZ:002734)2022-08-18 16:00Financial Performance - The company's operating revenue for the first half of 2022 was ¥2,808,692,569.18, representing a 10.56% increase compared to ¥2,540,464,320.04 in the same period last year[22]. - The net profit attributable to shareholders decreased by 38.80% to ¥151,327,409.03 from ¥247,259,941.59 year-on-year[22]. - Basic earnings per share fell by 37.88% to ¥0.41, down from ¥0.66 in the same period last year[22]. - The company reported a decrease of 40.26% in net profit after deducting non-recurring gains and losses, amounting to ¥143,201,850.06 compared to ¥239,722,888.27 last year[22]. - The weighted average return on net assets decreased to 5.08% from 9.91% in the previous year, reflecting a decline of 4.83%[22]. - The company's net profit after deducting non-recurring gains and losses for the first half of 2022 was 15,108.3 million yuan, a decrease of 42.09% compared to the same period last year[181]. - The net profit for the first half of 2022 was CNY 159,208,488.86, a decrease of 40.7% from CNY 268,434,861.18 in the first half of 2021[194]. - The total comprehensive income for the first half of 2022 was CNY 160,135,316.13, compared to CNY 268,164,297.59 in the same period of 2021[195]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching ¥252,291,219.60, compared to a negative cash flow of ¥282,707,788.97 in the previous year, marking a 189.24% increase[22]. - Cash and cash equivalents at the end of the reporting period amounted to 1,272,853,600, representing 16.54% of total assets, an increase of 2.45% compared to the previous year[54]. - The company's cash interest coverage ratio improved to 6.55, a significant increase of 179.88% compared to -8.2 in the previous year[181]. - Operating cash flow for the first half of 2022 was CNY 252,291,219.60, compared to a negative cash flow of CNY -282,707,788.97 in the first half of 2021[200]. Assets and Liabilities - Total assets increased by 11.83% to ¥7,697,795,509.02 from ¥6,883,292,562.29 at the end of the previous year[22]. - The company's total liabilities increased to CNY 1,530,770,268.11, compared to CNY 1,202,865,554.25 in the previous year, reflecting a growth of 27.3%[194]. - The company's asset-liability ratio increased to 64.15% as of June 30, 2022, up from 58.17% at the end of 2021, representing a 5.98% increase[179]. - Total liabilities amounted to CNY 4.94 billion, up from CNY 4.00 billion, which is an increase of about 23.5%[188]. Investments and R&D - The company's R&D investment decreased by 8.16% to ¥82,025,940.12 from ¥89,309,896.54 year-on-year[47]. - The company has established five R&D platforms and is actively exploring new technology applications in "new energy materials" and "synthetic biology," including a joint venture for lithium battery chemical research and production[40]. - The company is focusing on technological upgrades and new product development to maintain competitive advantages and create new profit points[75]. Market Presence and Strategy - The company is recognized as a leading domestic pesticide manufacturer, with significant production capacity in key products such as mancozeb and flumioxazin[34]. - The company’s products have received various international certifications, including FDA and GMP, enhancing its competitive edge[35]. - The company’s sales market covers over 130 countries and regions, indicating a strong international presence[34]. - The company is focusing on green and safe agricultural practices, aligning with national policies for sustainable development in the pesticide industry[32]. Environmental Compliance - The company is committed to improving its environmental governance and carbon reduction capabilities in response to increasing ESG standards[75]. - The company has implemented continuous monitoring systems to ensure ongoing compliance with environmental standards[86]. - The company has established 3 comprehensive wastewater treatment facilities with a daily processing capacity of 8,300 tons, ensuring wastewater meets discharge standards before entering the local sewage treatment plant[89]. Safety and Risk Management - The company has a dedicated safety management team with 27 safety management personnel and 19 registered safety engineers to oversee production safety[105]. - The company emphasizes environmental protection and adheres to national standards, achieving no major safety accidents in the first half of 2022[104]. - The company has established a comprehensive emergency response plan, conducting 1 company-level emergency drill and 12 on-site drills in the first half of 2022[111]. Shareholder and Governance - The largest shareholder, Li Ming, holds 19.79% of the shares, totaling 73,734,050, with 28,580,000 shares pledged[160]. - The company has implemented stock incentive plans for executives, with various amounts of shares being released from restrictions[157]. - The company reported a total of 20,729 ordinary shareholders at the end of the reporting period[159]. Legal and Regulatory Compliance - There were no significant legal disputes or regulatory penalties reported during the reporting period[123]. - The company has adhered to the commitments made regarding compliance and operational responsibilities during the asset restructuring process[115].